Literature DB >> 17602900

Quantitative determination of olmesartan in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry.

Dongyang Liu1, Pei Hu, Nobuko Matsushima, Xiaoming Li, Li Li, Ji Jiang.   

Abstract

A specific, sensitive and fast method based on high performance liquid chromatography coupled to tandem mass spectrometry (HPLC-MS/MS) was developed for the determination of olmesartan in human plasma and urine. Solid-phase extraction (SPE) was used to isolate the compounds from biological matrix followed by injection of the extracts onto a C(18) column with isocratic elution. The method was validated over the concentration range of 0.2-1000 and 5-10,000 ng/mL for olmesartan in human plasma and urine, respectively. The method was applied to the pharmacokinetic study of olmesartan medoxomil in healthy Chinese male and female subjects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17602900     DOI: 10.1016/j.jchromb.2007.05.049

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  10 in total

1.  Multivariate versus classical univariate calibration methods for spectrofluorimetric data: application to simultaneous determination of olmesartan medoxamil and amlodipine besylate in their combined dosage form.

Authors:  Hany W Darwish; Ahmed H Backeit
Journal:  J Fluoresc       Date:  2012-08-16       Impact factor: 2.217

2.  Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension.

Authors:  Devender Kodati; Harish Kaushik Kotakonda; Narsimhareddy Yellu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-08       Impact factor: 2.441

3.  RP-LC and HPTLC Methods for the Determination of Olmesartan Medoxomil and Hydrochlorothiazide in Combined Tablet Dosage Forms.

Authors:  P D Bari; A R Rote
Journal:  Chromatographia       Date:  2009-05-05       Impact factor: 2.044

4.  Spectrophotometric estimation of olmesartan medoxomil and hydrochlorothiazide in tablet.

Authors:  A R Rote; P D Bari
Journal:  Indian J Pharm Sci       Date:  2010-01       Impact factor: 0.975

5.  Ratio spectra derivative and zero-crossing difference spectrophotometric determination of olmesartan medoxomil and hydrochlorothiazide in combined pharmaceutical dosage form.

Authors:  Ambadas R Rote; Pankaj D Bari
Journal:  AAPS PharmSciTech       Date:  2009-10-28       Impact factor: 3.246

6.  Development of a novel 96-microwell assay with high throughput for determination of olmesartan medoxomil in its tablets.

Authors:  Ibrahim A Darwish; Tanveer A Wani; Nasr Y Khalil; Abdul-Aziz Al-Shaikh; Najm Al-Morshadi
Journal:  Chem Cent J       Date:  2012-01-03       Impact factor: 4.215

7.  Application of a Stability-Indicating HPTLC Method for Simultaneous Quantitative Determination of Olmesartan Medoxomil and Hydrochlorothiazide in Pharmaceutical Dosage Forms.

Authors:  Kaliappan Ilango; Pushpangadhan S Shiji Kumar
Journal:  J Anal Methods Chem       Date:  2013-11-04       Impact factor: 2.193

8.  Validated Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Azelnidipine and Olmesartan in Their Combined Dosage Form.

Authors:  Jayvadan K Patel; Nilam K Patel
Journal:  Sci Pharm       Date:  2014-02-27

9.  Novel and validated titrimetric method for determination of selected angiotensin-II-receptor antagonists in pharmaceutical preparations and its comparison with UV spectrophotometric determination.

Authors:  Shrikant H Patil; Minakshi V Janjale
Journal:  J Pharm Anal       Date:  2012-04-09

10.  Development of an HPLC-UV Method for the Analysis of Drugs Used for Combined Hypertension Therapy in Pharmaceutical Preparations and Human Plasma.

Authors:  Serife Evrim Kepekci Tekkeli
Journal:  J Anal Methods Chem       Date:  2013-03-24       Impact factor: 2.193

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.